Symbols

PSTX(Delisted)

Poseida Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 1

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PSTX

Poseida Therapeutics, Inc.

A clinical-stage biopharmaceutical company that develops gene therapies for hematological malignancies and solid tumors

Industry

Established Date

12/16/2014

Listing Date

07/10/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

330

Fiscal Year Ends

12-31

Website

www.poseida.com

Security Type

Common stock

Office address

9390 Towne Centre Drive, Suite 200, San Diego, CA 92121

Business

Introduction

Poseida Therapeutics, Inc., was incorporated under the laws of the State of Delaware on December 16, 2014. The company is a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases. The company's proprietary genetic engineering technology is used to create product candidates consisting primarily of specific T cell subpopulations, stem cell memory or TSCM, with the goal of compensating for the limitations of CAR-T therapies, including treatment duration, therapeutic capacity for solid tumors and tolerability issues. The company believes that the experience of the company's management team in cell and genetic engineering will help rapid development, and hopes to obtain approval to commercialize potential therapeutic cell and gene therapies.

Company Financials

EPS

PSTX has released its 2024 Q3 earnings. EPS was reported at 0.21, versus the expected -0.41, beating expectations. The chart below visualizes how PSTX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

PSTX has released its 2024 Q3 earnings report, with revenue of 71.75M, reflecting a YoY change of 667.19%, and net profit of 20.23M, showing a YoY change of 163.68%. The Sankey diagram below clearly presents PSTX's revenue sources and cost distribution.